Navigation Links
Codexis Appoints Interim Chief Executive Officer
Date:2/17/2012

REDWOOD CITY, Calif., Feb. 17, 2012 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a developer of industrial enzymes to enable the production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced that effective immediately, the Board of Directors has appointed Peter Strumph as the company's interim Chief Executive Officer.  Alan Shaw, Ph.D. has resigned as President and Chief Executive Officer and from the Board of Directors to pursue other interests.  He will continue to serve as a special advisor to the Board of Directors.  The Board of Directors has appointed a special committee that will oversee the CEO search and transition.  Heidrick & Struggles has been retained for a worldwide search, which will include both internal and external candidates.

"We are grateful to Alan for his many years of service in leading Codexis from its inception and are pleased that he has agreed to serve as a special advisor to the Board," said Thomas Baruch, Chairman of the Board for Codexis, Inc.  "We are confident that Peter's executive leadership experience and deep understanding of the business will ensure a smooth transition during our search for a permanent CEO."

"Codexis has a tremendous leadership team in place, and I am pleased to continue supporting the company as it works to commercialize industrial enzymes in the biofuel, chemical and pharmaceutical industries," said Dr. Shaw.

Mr. Strumph was the Senior Vice President and Business Head of Pharmaceuticals, where he oversaw a 49% annual increase in pharmaceutical product sales in 2011, as well as the Senior Vice President of Commercial Operations since joining Codexis in 2010.  Mr. Strumph has more than twenty years experience in senior manufacturing and operations management in the biopharmaceutical industry, including executive leadership positions for ten years at CV Therapeutics where he managed their operational, development and commercial activities.  He is a former Naval officer, and holds an MBA from the University of Pennsylvania's Wharton School of Business.   

About Codexis, Inc.

Codexis, Inc. is a developer of industrial enzymes to enable the production of biofuels, bio-based chemicals and pharmaceutical intermediates.  Codexis' product lines include CodeXyme™ Cellulase Enzymes and CodeXol™ Detergent Alcohol.  Partners and customers include global leaders such as Shell, Merck and Pfizer.  For more information, see www.codexis.com.

 

Contacts:
Investors: Jay Sarwar, ir@codexis.com, 650-421-8126
Media: Wes Bolsen, media@codexis.com, 650-421-8100


'/>"/>
SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Codexis Announces CFO Departure
2. Codexis to Announce Fourth Quarter and Fiscal Year 2011 Financial Results on February 7, 2012
3. Codexis Reports Third Quarter 2011 Results
4. 50 Pharma Companies Worldwide Now Use Codexis In Process Development
5. Codexis Names Veteran Chemical Executive to Lead Codexis do Brasil
6. Codexis, Raizen to Develop First Generation Ethanol
7. Codexis to Present at Three Investor Conferences in September
8. Codexis Presents Carbon Capture Update at DoE/NETL Conference
9. Codexis Board Elects Pedro I. Mizutani, Raizen EVP, as Director
10. Codexis Reports Second Quarter 2011 Results
11. Codexis and Chemtex to Collaborate on Sustainable Detergent Alcohols for the Household Products Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... year-end 2015 results after the Nasdaq market closes on ... live conference call and webcast to discuss its financial ... 11, 2016 at 4:30 p.m. Eastern Time (1:30 p.m. ... http://www.neurocrine.com . --> Participants can access the ...
(Date:2/8/2016)... -- http://www.researchandmarkets.com/research/fqx6nz/global_skin ) has announced ... Equipment Market 2016-2020" report to their offering. ... announced the addition of the "Global Skin ... offering. --> Research and ... of the "Global Skin Protective Equipment Market ...
(Date:2/8/2016)... --  Intarcia Therapeutics, Inc. today announced the appointment ... newly created role of Vice President, Head of Global ... decades of leadership experience at leading pharmaceutical, biotechnology, and ... center. Most recently Dr. Yee served as VP, Head ... Medical Officer at AstraZeneca, where he led medical affairs ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... ... famous for gift giving with flowers, chocolates and other tokens of affection meant to remind ... than 5.6 million Americans suffering with Alzheimer’s, those store bought gifts - no matter ... they’ve led and the people they’ve touched. , That’s why Give To ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... announced expansion into Canada to provide its range of unique and advantaged ... in Quebec City that will provide bilingual customer service and marketing support. A ...
(Date:2/8/2016)... ... 08, 2016 , ... Delta Dental of California and its affiliated companies announced ... D. Radine, who recently retired as president and CEO of Delta Dental of California ... of the Year , helped lead the effort to raise funds for studies to ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... of organizations. DocuSyst provides a cloud hosted environment for FileHold software that ... integration with various 3rd party applications using the FileHold web services API. DocuSyst ...
(Date:2/8/2016)... ... February 08, 2016 , ... TopConsumerReviews.com recently awarded their ... removal products. , Moles are derived from a cluster of melanin when exposed to ... wrong places and create a lifetime of embarrassment. Historically, mole removal has ...
Breaking Medicine News(10 mins):